Skip to main
OBIO
OBIO logo

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. demonstrates a favorable financial outlook, highlighted by a total revenue of $987,000 for the third quarter of 2024, surpassing projections of $750,000. The company has also amended the BACKBEAT study protocol, which is anticipated to broaden the eligible patient pool for hypertensive treatments and enhance enrollment speed in the forthcoming months. Furthermore, the net loss of $15.4 million or ($0.41) per share was less than the estimated loss of $16.5 million, indicating improved operational efficiency and financial management.

Bears say

Orchestra BioMed Holdings Inc faces significant risks that could negatively impact its stock performance, including the potential failure of its key product candidates, BackBeat CNT and Virtue SAB, during clinical trials and their inability to secure necessary regulatory approvals. Additionally, there is a concern regarding the commercial viability of these products, as competition and the overall market size may hinder successful market penetration. The risk of potential dilution also presents a financial challenge, further complicating the company's growth prospects and investor confidence.

OBIO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 7 analysts, OBIO has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.